An Immunohistochemistry study demonstrated that in high-grade (WHO grade III–IV) glioma samples, there was a clustering of antigen expression into “distinct neighborhoods.”53 For example, in areas of pseudopalisading necrosis, IL-13Rα2 and HER2 were expressed, but EGFR was not. This evidence concerns the gene ERBB2 and central nervous system cancer.